Mirae Asset Global Investments Co. Ltd. Boosts Stake in Edwards Lifesciences Co. (NYSE:EW)

Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 33.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 278,234 shares of the medical research company’s stock after acquiring an additional 69,740 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Edwards Lifesciences were worth $26,069,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Truvestments Capital LLC increased its holdings in Edwards Lifesciences by 260.0% during the 2nd quarter. Truvestments Capital LLC now owns 270 shares of the medical research company’s stock worth $25,000 after purchasing an additional 195 shares during the last quarter. Castleview Partners LLC bought a new stake in shares of Edwards Lifesciences in the first quarter worth $25,000. Altshuler Shaham Ltd acquired a new stake in Edwards Lifesciences in the second quarter valued at $31,000. Northwest Capital Management Inc bought a new position in Edwards Lifesciences during the 2nd quarter valued at $34,000. Finally, Jones Financial Companies Lllp acquired a new stake in shares of Edwards Lifesciences during the 1st quarter valued at approximately $33,000. Institutional investors and hedge funds own 79.25% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on EW. Royal Bank of Canada decreased their price objective on shares of Edwards Lifesciences from $86.00 to $82.00 and set an “outperform” rating for the company in a report on Thursday, October 26th. Jefferies Financial Group lifted their target price on Edwards Lifesciences from $103.00 to $107.00 and gave the company a “buy” rating in a research note on Tuesday, July 25th. Mizuho lowered their price target on Edwards Lifesciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, October 26th. Piper Sandler reduced their price objective on shares of Edwards Lifesciences from $83.00 to $68.00 and set a “neutral” rating for the company in a report on Thursday, October 26th. Finally, TheStreet cut shares of Edwards Lifesciences from a “b-” rating to a “c+” rating in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $84.29.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $67.19 on Tuesday. The company has a market capitalization of $40.75 billion, a P/E ratio of 28.71, a price-to-earnings-growth ratio of 3.74 and a beta of 1.02. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.28 and a quick ratio of 2.45. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $94.87. The business’s 50-day moving average price is $68.93 and its two-hundred day moving average price is $79.38.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, October 25th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.59. Edwards Lifesciences had a net margin of 24.59% and a return on equity of 24.54%. The firm had revenue of $1.48 billion during the quarter, compared to analysts’ expectations of $1.48 billion. During the same period in the previous year, the company earned $0.61 earnings per share. The company’s revenue was up 12.3% compared to the same quarter last year. Analysts anticipate that Edwards Lifesciences Co. will post 2.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $76.69, for a total transaction of $115,035.00. Following the transaction, the vice president now directly owns 23,950 shares in the company, valued at $1,836,725.50. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, insider Larry L. Wood sold 8,660 shares of Edwards Lifesciences stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $65.30, for a total value of $565,498.00. Following the transaction, the insider now directly owns 213,794 shares in the company, valued at $13,960,748.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daveen Chopra sold 1,500 shares of the stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $76.69, for a total value of $115,035.00. Following the completion of the sale, the vice president now directly owns 23,950 shares of the company’s stock, valued at $1,836,725.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 179,795 shares of company stock worth $12,724,914. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.